Laser & Skin Surgery Center of New York, New York, New York2Ronald O. Perelman Department of Dermatology, NYU Langone Medical Center, New York, New York.
Ackerman Academy Dermatopathology, New York, New York.
JAMA Dermatol. 2015 Mar;151(3):278-84. doi: 10.1001/jamadermatol.2014.3045.
Fractional laser technology is routinely used in the treatment of acne scarring, with thermal injury resulting in collagen synthesis and remodeling. Use of a picosecond pulse duration with a diffractive lens array may be a new technologic advancement in the treatment of acne scarring.
To investigate the safety and efficacy of a 755-nm alexandrite picosecond pulse duration laser with diffractive lens array for the treatment of facial acne scarring.
DESIGN, SETTING, AND PARTICIPANTS: This single-center, prospective study performed in a private practice with a dedicated research department included patients with clinically diagnosed scarring secondary to inflammatory or cystic acne.
Patients received 6 treatments with a 755-nm picosecond laser with a spot size of 6 mm, fluence of 0.71 J/cm2, repetition rate of 5 Hz, and pulse width of 750 picoseconds in combination with a diffractive lens array, allowing for greater surface area and pattern density per pulse.
The pain and satisfaction scores for overall appearance and texture were recorded. Masked assessment of clinical photographs and analysis of 3-dimensional volumetric data were performed. Biopsy specimens were obtained for independent histologic evaluation by 2 investigators at baseline and at 3 months after last treatment.
Fifteen women and 5 men (mean age, 44 years; age range, 27-61 years) with Fitzpatrick skin types I through V and facial acne scarring were enrolled. The mean pain score was 2.83 of 10. Patients were satisfied to extremely satisfied with improvement in appearance and texture at their final treatment and follow-up visits. The masked assessment scores of 17 patients were 1.5 of 3 and 1.4 of 3 at 1 and 3 months, respectively (a score of 0 indicates 0%-25% improvement and a score of 3 indicates >75% improvement). A 3-dimensional analysis revealed a mean 24.3% improvement in scar volume, maintained at 1 (24.0%) and 3 (27.2%) months after treatment. Histologic analysis revealed elongation and increased density of elastic fibers, with an increase in dermal collagen and mucin.
Treatment of facial acne scars with a diffractive lens array and 755-nm picosecond laser produced improvement in appearance and texture at 3 months after the last treatment, with objective findings similar to those published for a series of fractional ablative laser treatments. Histologic findings suggest that improvement in scarring from this treatment goes beyond remodeling of collagen.
分激光技术通常用于治疗痤疮疤痕,热损伤导致胶原蛋白合成和重塑。 使用具有衍射透镜阵列的皮秒脉冲持续时间可能是治疗痤疮疤痕的新技术进步。
研究 755nm 翠绿宝石皮秒脉冲持续时间激光联合衍射透镜阵列治疗面部痤疮疤痕的安全性和疗效。
设计、地点和参与者: 这项单中心前瞻性研究在一家私人诊所进行,该诊所设有专门的研究部门,纳入了患有炎症性或囊性痤疮继发疤痕的临床诊断为疤痕的患者。
患者接受了 6 次治疗,使用 755nm 皮秒激光,光斑大小为 6mm,能量密度为 0.71J/cm2,重复频率为 5Hz,脉冲宽度为 750 皮秒,并结合了衍射透镜阵列,允许更大的表面积和每脉冲的图案密度。
记录整体外观和质地的疼痛和满意度评分。 对临床照片进行了掩蔽评估,并对 3 维体积数据进行了分析。 在基线和最后一次治疗后 3 个月,由 2 名研究人员获取活检标本进行独立的组织学评估。
15 名女性和 5 名男性(平均年龄 44 岁;年龄范围 27-61 岁),皮肤类型为 I 至 V 型,面部痤疮疤痕。 平均疼痛评分为 10 分的 2.83 分。 患者对治疗和随访结束时的外观和质地改善非常满意。 17 名患者的掩蔽评估评分分别为 1 个月时的 1.5/3 和 3 个月时的 1.4/3(评分 0 表示改善 0%-25%,评分 3 表示改善>75%)。 3 维分析显示疤痕体积平均改善 24.3%,治疗后 1 个月(24.0%)和 3 个月(27.2%)保持不变。 组织学分析显示弹性纤维伸长和密度增加,真皮胶原和粘蛋白增加。
采用衍射透镜阵列和 755nm 皮秒激光治疗面部痤疮疤痕,可在最后一次治疗后 3 个月改善外观和质地,客观发现与一系列分激光消融治疗系列相似。 组织学发现表明,这种治疗方法改善疤痕的效果不仅限于胶原重塑。